ELDEC PHARMACEUTICALS INC.
Durham, NC · CIK 0002110508 · Biotech · Private
Novel peptide immunomodulators (ELD607, a SPLUNC1 peptidomimetic) that inhibit Orai1 calcium channels to reduce inflammatory responses in sepsis
eldecpharmaceuticals.com →- Grants
- $6.2M
- 13 awards
- Sector median: 1
- Raised
- $200K
- 1 Form D · Feb 2026
- 8 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Peptide therapies for treating CF lung inflammation | $224,865 | |
| Federal grant | Department of Health and Human Services · Phase I · Peptide therapies for treating CF lung inflammation | $224,865 | |
| Federal grant | Department of Health and Human Services · Phase II · ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | $999,840 | |
| Federal grant | Department of Health and Human Services · Phase II · ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | $988,238 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Strategies to Clear Bacteria from the CF Lung | $999,919 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel Peptide Fusion Inhibitors for the Treatment of COVID-19 | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Peptide Fusion Inhibitors for the Treatment of COVID-19 | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Strategies to Clear Bacteria from the CF Lung | $94,743 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel Peptide Immunomodulators for Treating Sepsis | $259,121 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Peptide Immunomodulators for Treating Sepsis | $259,121 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Strategies to Clear Bacteria from the CF Lung | $977,764 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel peptide therapeutics to treat cystic fibrosis-related diabetes | $280,122 | |
| Private capital raised | Form D · SEC | $200,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2628 | Daya CNS, LLC | — | $228K |
| 2629 | Zepteon, Inc | — | $210K |
| 2630 | VERRA THERAPEUTICS LLC | — | $205K |
| 2631 | ELDEC PHARMACEUTICALS INC. | — | $200K |
| 2632 | Reven Holdings Inc | — | $200K |
| 2633 | NonExomics, Inc. | — | $200K |
| 2634 | FruitVaccine Incorporation | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Robert SchotzingerDirector · Executive Officer
- Robert TarranDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.